FDA Authorizes IND For Phase 2 Clinical Trial Evaluating Treatment for Post–COVID-19 Condition

The FDA has authorized BioVie's investigational new drug application for bezisterim to treat neurological symptoms associated with post–COVID-19 condition. A phase 2 trial will evaluate bezisterim's safety, tolerability, and potential to reduce neurocognitive symptoms in 200 patients over 3 months. Bezisterim, which acts on inflammatory pathways, is also being investigated for Alzheimer Disease and Parkinson Disease.


Related News

FDA Authorizes New Drug Application For Trial to Evaluate Treatment for Long COVID

BioVie Inc's FDA-authorized phase 2 trial will evaluate bezisterim for long COVID, aiming to reduce neurocognitive symptoms. Bezisterim, an anti-inflammatory insulin sensitizer, also shows promise in Alzheimer and Parkinson diseases.

FDA Authorizes IND For Phase 2 Clinical Trial Evaluating Treatment for Post–COVID-19 Condition

The FDA has authorized BioVie's investigational new drug application for bezisterim to treat neurological symptoms associated with post–COVID-19 condition. A phase 2 trial will evaluate bezisterim's safety, tolerability, and potential to reduce neurocognitive symptoms in 200 patients over 3 months. Bezisterim, which acts on inflammatory pathways, is also being investigated for Alzheimer Disease and Parkinson Disease.

© Copyright 2024. All Rights Reserved by MedPath